The scientists at Imperial College in London, United Kingdom may have discovered a way to outsmart the common cold. Instead of considering the virus as the target, the new treatment will attack the human host which the cold virus needs.
The common cold is not at all easy to treat and cure as its symptoms are triggered by viruses that come in various versions. This makes it difficult for the body to get completely immune to or to vaccinate against them all. To top it all, the viruses develop quickly which is why they tend to gain resistance to any drugs rapidly.
It is due to these reasons that the best way to treat the common cold is by maintaining a good hygiene practice to avoid spreading of the virus and to manage the runny nose and scratchy or sore throat for the next 10 days that it may take to recover fully.
The research, published in the Nature Chemistry journal today, states the latest step to combat the common cold. The researchers have made a molecule that has shown to the ability to block the multiple strains of the most common cold virus, rhinovirus. The molecule targets the protein N-myristoyltransferase (NMT) found in the human cells, which each strain of the virus uses to multiply further.
The molecule, named as IMP-1088, comes with the ability to outsmart all the strains of the virus. And as the molecule targets the protein instead of the virus, it is not that likely that the virus will become resistant to it.
The earlier attempts that were made to develop drugs that target human host rather than the virus have failed as they proved to be very dangerous. However, the lab based test results of this molecule have shown no negative effect on the human cells.
The team of researchers now hope to conduct animal and human trials soon to known the efficiency of the IMP-1088.